Journal profile · Biochemistry & Molecular Biology
Prostaglandins & Other Lipid Mediators
ISSN 1098-8823 · eISSN 2212-196X · Elsevier Inc. · UNITED STATES · Monthly · Founded 1998
Prostaglandins & Other Lipid Mediators: CAS Zone 3 · Biology (2025 upgraded edition); impact factor 2.52; hybrid open access; APC about USD 3,500; median 131 days to acceptance (91 articles, last 24 months); community-reported acceptance: about 75%; 46 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Prostaglandins & Other Lipid Mediators is published by Elsevier Inc. and is in Zone 3 of Biology in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Inflammatory mediators and NSAID effects, Eicosanoids and Hypertension Pharmacology and Estrogen and related hormone effects, together about 37.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Prostaglandins & Other Lipid Mediators is the original and foremost journal dealing with prostaglandins and related lipid mediator substances. It includes basic and clinical studies related to the pharmacology, physiology, pathology and biochemistry of lipid mediators.Prostaglandins & Other Lipid Mediators invites reports of original research, mini-reviews, reviews, and methods articles in the basic and clinical aspects of all areas of lipid mediator research: cell biology, developmental biology, genetics, molecular biology, chemistry, biochemistry, physiology, pharmacology, endocrinology, biology, the medical sciences, and epidemiology. Systematic reviews and meta-analysis studies will not be acceptable for publication.Prostaglandins & Other Lipid Mediators also accepts proposals for special issue topics. The Editors will make every effort to advise authors of the decision on the submitted manuscript within 3-4 weeks of receipt.US National Institutes of Health (NIH) voluntary posting ("Public Access") policy Prostaglandins & Other Lipid Mediators and Elsevier facilitate the author's response to the NIH Public Access Policy.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry & Molecular Biology
Editor-in-chief Austin GuoPublisher website
Editorial board by country: 1 in mainland China (about 3%); most named United States 18, Germany 4, Australia 3, United Kingdom 2, Mainland China 1 (31 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Inflammatory mediators and NSAID effectsMedicine16.3%
- Eicosanoids and Hypertension PharmacologyBiochemistry, Genetics and Molecular Biology14.8%
- Estrogen and related hormone effectsBiochemistry, Genetics and Molecular Biology6.6%
- Fatty Acid Research and HealthNursing5.6%
- Peroxisome Proliferator-Activated ReceptorsBiochemistry, Genetics and Molecular Biology5.2%
- Sphingolipid Metabolism and SignalingBiochemistry, Genetics and Molecular Biology4.4%
- Nitric Oxide and Endothelin EffectsMedicine4.2%
- Human auditory perception and evaluationEngineering3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Biology Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
| Minor | Cell Biology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Biology Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
| Minor | Cell Biology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Biology Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Biology | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
| Minor | Cell Biology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.52LetPub ·
- Impact factor (publisher)
- 2.6Publisher website ·
- CiteScore 2026-06
- 4.5LetPub ·
- CiteScore (publisher)
- 4.5Publisher website ·
- SJR 2026-06
- 0.7LetPub ·
- SNIP 2026-06
- 0.67LetPub ·
- h-index
- 67LetPub ·
- h-index
- 96OpenAlex ·
- i10-index
- 1,034OpenAlex ·
- 2-year mean citedness
- 3.66OpenAlex ·
- Self-citation rate
- 3.8%LetPub ·
- Share of gold OA articles
- 16.76%LetPub ·
Volume
- Articles per year
- 40LetPub ·
Articles by year OpenAlex count · 2,036 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 37 | 9 | 7 |
| 2025 | 46 | 12 | 149 |
| 2024 | 97 | 25 | 503 |
| 2023 | 64 | 19 | 579 |
| 2022 | 50 | 15 | 465 |
| 2021 | 48 | 13 | 531 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
131 daysMedian, submission to acceptance · P25–P75 85 days – 158 days
- Acceptance to online
- median 2 days (91 articles)
- Submission to online
- median 135 days
- Sample
- 91 articles with submission and acceptance dates (111 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 75%LetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- First decision after review
- 90 daysPublisher website ·
- Submission to acceptance
- 138 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,500 / EUR 3,270 / GBP 2,800 / JPY 434,110 | — | — | |
| Publisher website | USD 3,450 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare7 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Highlights
- Required
- Cover letter
- Required
- Not considered
- Bibliometric Analysis; Mendelian Randomization Study; Systematic reviews and meta-analysis studies
Article types accepted7
- methods article• Original research reports• Minireviews• Reviews• Methods articles*Prostaglandins and Other Lipid Mediators does not entertain Bibliometric Analysis or Mendeli…Length not stated
- methods articles• Methods articlesLength not stated
- minireviews• MinireviewsLength not stated
- original research• Original research reports• Minireviews• Reviews• Methods articles*Prostaglandins and Other Lipid Mediators does not entertain Bibliometric Analysis or Mendeli…Length not stated
- original research reports• Original research reportsLength not stated
- review• Original research reports• Minireviews• Reviews• Methods articles*Prostaglandins and Other Lipid Mediators does not entertain Bibliometric Analysis or Mendeli…Length not stated
- reviews• ReviewsLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of one reviewer for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Rea…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1998
- ISSN
- 1098-8823
- Electronic ISSN
- 2212-196X
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Prostaglandins & Other Lipid Mediators
What CAS zone is Prostaglandins & Other Lipid Mediators in?
In the 2025 upgraded edition of the CAS Journal Ranking, Prostaglandins & Other Lipid Mediators is in Zone 3 of Biology, and in Zone 4 of the minor category Biochemistry & Molecular Biology / Cell Biology. In the 2026 Xinrui edition it is in Zone 3 of Biology. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Prostaglandins & Other Lipid Mediators?
The latest impact factor listed by LetPub is 2.52; CiteScore 4.5, h-index 96.
How long does peer review take at Prostaglandins & Other Lipid Mediators?
Based on the dates recorded on 91 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 131 days (interquartile range 85–158 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 75%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Prostaglandins & Other Lipid Mediators?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; Suggested reviewers: Optional; Highlights: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Prostaglandins & Other Lipid Mediators based?
Of the 31 board members whose country the journal's board page names, 1 (about 3%) are in mainland China; the countries named most often are United States (18), Germany (4) and Australia (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Prostaglandins & Other Lipid Mediators?
According to LetPub and DOAJ records, Prostaglandins & Other Lipid Mediators is indexed in SCIE and Scopus.
Is Prostaglandins & Other Lipid Mediators open access, and what is the APC?
Prostaglandins & Other Lipid Mediators is a hybrid journal. For open-access publication: APC about USD 3,500.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .